Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Aug 25, 2022 11:51am
292 Views
Post# 34919983

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:WOW!

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:WOW!
Funny how a 4 billion dollar U.S. offer could be considered a lowball offer and yet that is a possibility. If indeed that were the case then what exactly is Matt and company looking for. I mean really, I do not think any shareholder would turn down approx. 60 dollars a share at this point. I think that an offer like that would have to be presented to shareholders for consideration unless the negotiations were still active. I mean really, would it be fair for ONC to not present a 4 billion dollar offer to shareholders at this point especially with no guarantee that future trials will for sure prove out. Having said that, we do not know what may or may not have been presented but management needs to consider the time this company has been around  and long term shareholders and not just the interest of management.
<< Previous
Bullboard Posts
Next >>